{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:15:02Z","timestamp":1790759702546,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While improvements in immunoradiotherapy have significantly improved outcomes for cancer patients, this treatment approach has nevertheless proven ineffective at controlling the majority of malignancies. One of the mechanisms of resistance to immunoradiotherapy is that immune cells may be suppressed via the myriad of different immune checkpoint receptors. Therefore, simultaneous blockade of multiple immune checkpoint receptors may enhance the treatment efficacy of immunoradiotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We combined NBTXR3-enhanced localized radiation with the simultaneous blockade of three different checkpoint receptors: PD1, LAG3, and TIGIT, and tested the treatment efficacy in an anti-PD1-resistant lung cancer model in mice. 129\u00a0Sv\/Ev mice were inoculated with fifty thousand \u03b1PD1-resistant 344SQR cells in the right leg on day 0 to establish primary tumors and with the same number of cells in the left leg on day 4 to establish the secondary tumors. NBTXR3 was intratumorally injected into the primary tumors on day 7, which were irradiated with 12\u00a0Gy on days 8, 9, and 10. Anti-PD1 (200\u00a0\u00b5g), \u03b1LAG3 (200\u00a0\u00b5g), and \u03b1TIGIT (200\u00a0\u00b5g) were given to mice by intraperitoneal injections on days 5, 8, 11, 14, 21, 28, 35, and 42.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This nanoparticle-mediated combination therapy is effective at controlling the growth of irradiated and distant unirradiated tumors, enhancing animal survival, and is the only one that led to the destruction of both tumors in approximately 30% of the treated mice. Corresponding with this improved response is robust activation of the immune response, as manifested by increased numbers of immune cells along with a transcriptional signature of both innate and adaptive immunity within the tumor. Furthermore, mice treated with this combinatorial therapy display immunological memory response when rechallenged by the same cancer cells, preventing tumor engraftment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results strongly attest to the efficacy and validity of combining nanoparticle-enhanced radiotherapy and simultaneous blockade of multiple immune checkpoint receptors and provide a pre-clinical rationale for investigating its translation into human patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-022-01621-4","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T07:03:12Z","timestamp":1663570992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Yun","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Bertolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampartsoum B.","family":"Barsoumian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Sezen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan DA","family":"SILVA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joylise A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany A.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Masrorpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Kettlun","family":"Leyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Leuschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahum","family":"Puebla-Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumil","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh-Nhu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angelica","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"issue":"8","key":"1621_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2217\/imt-2017-0024","volume":"9","author":"AW Hahn","year":"2017","unstructured":"Hahn AW, Gill DM, Pal SK, Agarwal N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017;9(8):681\u201392.","journal-title":"Immunotherapy"},{"issue":"17","key":"1621_CR2","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.2174\/0929867324666170804143706","volume":"26","author":"B Li","year":"2019","unstructured":"Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26(17):3009\u201325.","journal-title":"Curr Med Chem"},{"issue":"10","key":"1621_CR3","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3109\/0284186X.2015.1071918","volume":"54","author":"X Li","year":"2015","unstructured":"Li X, Hu W, Zheng X, Zhang C, Du P, Zheng Z, Yang Y, Wu J, Ji M, Jiang J, et al. Emerging immune checkpoints for cancer therapy. Acta Oncol. 2015;54(10):1706\u201313.","journal-title":"Acta Oncol"},{"issue":"1","key":"1621_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1621_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.","journal-title":"Mol Cancer"},{"issue":"3","key":"1621_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"RK Vaddepally","year":"2020","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of Indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738.","journal-title":"Cancers (Basel)."},{"issue":"6382","key":"1621_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science"},{"issue":"10","key":"1621_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.tcb.2019.07.002","volume":"29","author":"N Curdy","year":"2019","unstructured":"Curdy N, Lanvin O, Laurent C, Fournie JJ, Franchini DM. Regulatory mechanisms of inhibitory immune checkpoint receptors expression. Trends Cell Biol. 2019;29(10):777\u201390.","journal-title":"Trends Cell Biol"},{"issue":"1","key":"1621_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","volume":"23","author":"JE Kim","year":"2017","unstructured":"Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2017;23(1):124\u201336.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1621_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","volume":"6","author":"YK Chae","year":"2018","unstructured":"Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1621_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.7150\/thno.32648","volume":"9","author":"OM Ozpiskin","year":"2019","unstructured":"Ozpiskin OM, Zhang L, Li JJ. Immune targets in the tumor microenvironment treated by radiotherapy. Theranostics. 2019;9(5):1215\u201331.","journal-title":"Theranostics"},{"key":"1621_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejca.2017.08.014","volume":"85","author":"JM Michot","year":"2017","unstructured":"Michot JM, Lazarovici J, Ghez D, Danu A, Ferme C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. Eur J Cancer. 2017;85:67\u201377.","journal-title":"Eur J Cancer"},{"issue":"7","key":"1621_CR13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/1878-0261.12658","volume":"14","author":"M Mondini","year":"2020","unstructured":"Mondini M, Levy A, Meziani L, Milliat F, Deutsch E. Radiotherapy-immunotherapy combinations - perspectives and challenges. Mol Oncol. 2020;14(7):1529\u201337.","journal-title":"Mol Oncol"},{"issue":"8","key":"1621_CR14","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S1470-2045(19)30306-7","volume":"20","author":"SD Karam","year":"2019","unstructured":"Karam SD, Raben D. Radioimmunotherapy for the treatment of head and neck cancer. Lancet Oncol. 2019;20(8):e404-16.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1621_CR15","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1016\/S1470-2045(19)30401-2","volume":"20","author":"FG Herrera","year":"2019","unstructured":"Herrera FG, Irving M, Kandalaft LE, Coukos G. Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncol. 2019;20(8):e417-33.","journal-title":"Lancet Oncol"},{"key":"1621_CR16","doi-asserted-by":"publisher","first-page":"116713","DOI":"10.1016\/j.lfs.2019.116713","volume":"233","author":"H Memon","year":"2019","unstructured":"Memon H, Patel BM. Immune checkpoint inhibitors in non-small cell lung cancer: a bird\u2019s eye view. Life Sci. 2019;233:116713.","journal-title":"Life Sci"},{"issue":"1","key":"1621_CR17","first-page":"443","volume":"34","author":"A Pottier","year":"2014","unstructured":"Pottier A, Borghi E, Levy L. New use of metals as nanosized radioenhancers. Anticancer Res. 2014;34(1):443\u201353.","journal-title":"Anticancer Res"},{"issue":"4","key":"1621_CR18","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/1078-0432.CCR-16-1297","volume":"23","author":"S Bonvalot","year":"2017","unstructured":"Bonvalot S, Le Pechoux C, De Baere T, Kantor G, Buy X, Stoeckle E, Terrier P, Sargos P, Coindre JM, Lassau N, et al. First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas. Clin Cancer Res. 2017;23(4):908\u201317.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1621_CR19","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","volume":"20","author":"S Bonvalot","year":"2019","unstructured":"Bonvalot S, Rutkowski PL, Thariat J, Carr\u00e8re S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2\u20133, randomised, controlled trial. Lancet Oncol. 2019;20(8):1148\u201359.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1621_CR20","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ijrobp.2021.06.041","volume":"111","author":"Y Hu","year":"2021","unstructured":"Hu Y, Paris S, Barsoumian H, Abana CO, He K, Wasley M, Younes AI, Masrorpour F, Chen D, Yang L, et al. Radiation therapy enhanced by NBTXR3 nanoparticles overcomes anti-PD1 resistance and evokes abscopal effects. Int J Radiat Oncol Biol Phys. 2021;111(3):647\u201357.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1621_CR21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12951-021-01163-1","volume":"19","author":"Y Hu","year":"2021","unstructured":"Hu Y, Paris S, Barsoumian H, Abana CO, He K, Sezen D, Wasley M, Masrorpour F, Chen D, Yang L, et al. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. J Nanobiotechnol. 2021;19(1):416.","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"1621_CR22","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862\u201370.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1621_CR23","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.2147\/IJN.S250490","volume":"15","author":"P Zhang","year":"2020","unstructured":"Zhang P, Darmon A, Marill J, Mohamed Anesary N, Paris S. Radiotherapy-activated hafnium oxide nanoparticles produce abscopal effect in a mouse colorectal cancer model. Int J Nanomedicine. 2020;15:3843\u201350.","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"1621_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227\u201342.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1621_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41422-020-0285-x","volume":"30","author":"A Schnell","year":"2020","unstructured":"Schnell A, Bod L, Madi A, Kuchroo VK. Author correction: the yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Cell Res. 2020;30(4):366.","journal-title":"Cell Res"},{"key":"1621_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.canlet.2020.11.035","volume":"499","author":"HS Han","year":"2021","unstructured":"Han HS, Jeong S, Kim H, Kim HD, Kim AR, Kwon M, Park SH, Woo CG, Kim HK, Lee KH, et al. TOX-expressing terminally exhausted tumor-infiltrating CD8(+) T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Lett. 2021;499:137\u201347.","journal-title":"Cancer Lett"},{"issue":"2","key":"1621_CR27","doi-asserted-by":"publisher","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"JM Chauvin","year":"2020","unstructured":"Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1621_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","volume":"276","author":"LP Andrews","year":"2017","unstructured":"Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80\u201396.","journal-title":"Immunol Rev"},{"issue":"4","key":"1621_CR29","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res. 2017;77(4):839\u201350.","journal-title":"Cancer Res"},{"issue":"1","key":"1621_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/107999002753452700","volume":"22","author":"L Zhang","year":"2002","unstructured":"Zhang L, Pagano JS. Structure and function of IRF-7. J Interferon Cytokine Res. 2002;22(1):95\u2013101.","journal-title":"J Interferon Cytokine Res"},{"issue":"26","key":"1621_CR31","doi-asserted-by":"publisher","first-page":"23093","DOI":"10.1074\/jbc.M111.233304","volume":"286","author":"KB Kim","year":"2011","unstructured":"Kim KB, Yi JS, Nguyen N, Lee JH, Kwon YC, Ahn BY, Cho H, Kim YK, Yoo HJ, Lee JS, et al. Cell-surface receptor for complement component C1q (gC1qR) is a key regulator for lamellipodia formation and cancer metastasis. J Biol Chem. 2011;286(26):23093\u2013101.","journal-title":"J Biol Chem"},{"issue":"11","key":"1621_CR32","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1074\/mcp.M113.029413","volume":"12","author":"X Zhang","year":"2013","unstructured":"Zhang X, Zhang F, Guo L, Wang Y, Zhang P, Wang R, Zhang N, Chen R. Interactome analysis reveals that C1QBP (complement component 1, q subcomponent binding protein) is associated with cancer cell chemotaxis and metastasis. Mol Cell Proteomics. 2013;12(11):3199\u2013209.","journal-title":"Mol Cell Proteomics"},{"issue":"4","key":"1621_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/bjc.2016.428","volume":"116","author":"CM Gay","year":"2017","unstructured":"Gay CM, Balaji K, Byers LA. Giving AXL the axe: targeting AXL in human malignancy. Br J Cancer. 2017;116(4):415\u201323.","journal-title":"Br J Cancer"},{"issue":"5","key":"1621_CR34","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ijc.28246","volume":"134","author":"JD Paccez","year":"2014","unstructured":"Paccez JD, Vogelsang M, Parker MI, Zerbini LF. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer. 2014;134(5):1024\u201333.","journal-title":"Int J Cancer"},{"issue":"18","key":"1621_CR35","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1007\/s40265-014-0315-4","volume":"74","author":"JJ Luke","year":"2014","unstructured":"Luke JJ, Ott PA, Shapiro GI. The biology and clinical development of MEK inhibitors for cancer. Drugs. 2014;74(18):2111\u201328.","journal-title":"Drugs"},{"issue":"7651","key":"1621_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature22076","volume":"544","author":"J Chen","year":"2017","unstructured":"Chen J, Zhong MC, Guo H, Davidson D, Mishel S, Lu Y, Rhee I, P\u00e9rez-Quintero LA, Zhang S, Cruz-Munoz ME, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature. 2017;544(7651):493\u20137.","journal-title":"Nature"},{"issue":"2","key":"1621_CR37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1073\/pnas.97.2.817","volume":"97","author":"J Klucken","year":"2000","unstructured":"Klucken J, B\u00fcchler C, Ors\u00f3 E, Kaminski WE, Porsch-Ozc\u00fcr\u00fcmez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci U S A. 2000;97(2):817\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1621_CR38","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1161\/CIRCRESAHA.110.228619","volume":"108","author":"TA Pagler","year":"2011","unstructured":"Pagler TA, Wang M, Mondal M, Murphy AJ, Westerterp M, Moore KJ, Maxfield FR, Tall AR. Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling. Circ Res. 2011;108(2):194\u2013200.","journal-title":"Circ Res"},{"issue":"6","key":"1621_CR39","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.4049\/jimmunol.180.6.4273","volume":"180","author":"AJ Wojcik","year":"2008","unstructured":"Wojcik AJ, Skaflen MD, Srinivasan S, Hedrick CC. A critical role for ABCG1 in macrophage inflammation and lung homeostasis. J Immunol. 2008;180(6):4273\u201382.","journal-title":"J Immunol"},{"issue":"4","key":"1621_CR40","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.4049\/jimmunol.180.4.2650","volume":"180","author":"AC MacKinnon","year":"2008","unstructured":"MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, Sethi T. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008;180(4):2650\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"1621_CR41","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/cvr\/cvt273","volume":"101","author":"HT Shi","year":"2014","unstructured":"Shi HT, Wang Y, Jia LX, Qin YW, Liu Y, Li HH, Qi YF, Du J. Cathepsin S contributes to macrophage migration via degradation of elastic fibre integrity to facilitate vein graft neointimal hyperplasia. Cardiovasc Res. 2014;101(3):454\u201363.","journal-title":"Cardiovasc Res"},{"key":"1621_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bcp.2017.10.001","volume":"146","author":"S Thanei","year":"2017","unstructured":"Thanei S, Theron M, Silva AP, Reis B, Branco L, Schirmbeck L, Kolb FA, Haap W, Schindler T, Trendelenburg M. Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages. Biochem Pharmacol. 2017;146:151\u201364.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"1621_CR43","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1038\/s41467-018-07387-4","volume":"9","author":"MC Schmid","year":"2018","unstructured":"Schmid MC, Khan SQ, Kaneda MM, Pathria P, Shepard R, Louis TL, Anand S, Woo G, Leem C, Faridi MH, et al. Integrin CD11b activation drives anti-tumor innate immunity. Nat Commun. 2018;9(1):5379.","journal-title":"Nat Commun"},{"issue":"26","key":"1621_CR44","doi-asserted-by":"publisher","first-page":"6786","DOI":"10.1073\/pnas.1805542115","volume":"115","author":"J Wu","year":"2018","unstructured":"Wu J, Wu H, An J, Ballantyne CM, Cyster JG. Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47 cells to induce adaptive immunity. Proc Natl Acad Sci U S A. 2018;115(26):6786\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1621_CR45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.immuni.2015.03.009","volume":"42","author":"L Surace","year":"2015","unstructured":"Surace L, Lysenko V, Fontana AO, Cecconi V, Janssen H, Bicvic A, Okoniewski M, Pruschy M, Dummer R, Neefjes J, et al. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity. 2015;42(4):767\u201377.","journal-title":"Immunity"},{"issue":"3","key":"1621_CR46","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1053\/j.seminoncol.2019.07.003","volume":"46","author":"L Portella","year":"2019","unstructured":"Portella L, Scala S. Ionizing radiation effects on the tumor microenvironment. Semin Oncol. 2019;46(3):254\u201360.","journal-title":"Semin Oncol"},{"issue":"3","key":"1621_CR47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ni889","volume":"4","author":"EJ Wherry","year":"2003","unstructured":"Wherry EJ, Teichgr\u00e4ber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4(3):225\u201334.","journal-title":"Nat Immunol"},{"issue":"6","key":"1621_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","volume":"15","author":"SM Larson","year":"2015","unstructured":"Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15(6):347\u201360.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1621_CR49","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1158\/1078-0432.CCR-19-2034","volume":"26","author":"A Arina","year":"2020","unstructured":"Arina A, Gutiontov SI, Weichselbaum RR. Radiotherapy and immunotherapy for cancer: from \u201csystemic\u201d to \u201cmultisite\". Clin Cancer Res. 2020;26(12):2777\u201382.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1621_CR50","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259\u201371.","journal-title":"J Exp Med"},{"issue":"4","key":"1621_CR51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt-2017-0082","volume":"10","author":"ML Aliru","year":"2018","unstructured":"Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, Barsoumian HB, Younes AI, LS KM, Soeung M, Aziz KE, Welsh JW, et al. Radiation therapy and immunotherapy: what is the optimal timing or sequencing? Immunotherapy. 2018;10(4):299\u2013316.","journal-title":"Immunotherapy"},{"issue":"1","key":"1621_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijrobp.2020.05.011","volume":"108","author":"AY Ho","year":"2020","unstructured":"Ho AY, Wright JL, Blitzblau RC, Mutter RW, Duda DG, Norton L, Bardia A, Spring L, Isakoff SJ, Chen JH, et al. Optimizing radiation therapy to boost systemic immune responses in breast cancer: a critical review for breast radiation oncologists. Int J Radiat Oncol Biol Phys. 2020;108(1):227\u201341.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1621_CR53","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy? Nat Med. 2017;23(5):540\u20137.","journal-title":"Nat Med"},{"issue":"5","key":"1621_CR54","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"29","key":"1621_CR55","doi-asserted-by":"publisher","first-page":"27359","DOI":"10.18632\/oncotarget.4751","volume":"6","author":"RY Huang","year":"2015","unstructured":"Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8 + T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6(29):27359\u201377.","journal-title":"Oncotarget"},{"issue":"8","key":"1621_CR56","doi-asserted-by":"publisher","first-page":"e1466769","DOI":"10.1080\/2162402X.2018.1466769","volume":"7","author":"AL Hung","year":"2018","unstructured":"Hung AL, Maxwell R, Theodros D, Belcaid Z, Mathios D, Luksik AS, Kim E, Wu A, Xia Y, Garzon-Muvdi T, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology. 2018;7(8):e1466769.","journal-title":"Oncoimmunology"},{"issue":"23","key":"1621_CR57","doi-asserted-by":"publisher","first-page":"121062","DOI":"10.1172\/jci.insight.121062","volume":"3","author":"Y Sato","year":"2018","unstructured":"Sato Y, Bolzenius JK, Eteleeb AM, Su X, Maher CA, Sehn JK, Arora VK. CD4 + T cells induce rejection of urothelial tumors after immune checkpoint blockade. JCI Insight. 2018;3(23):121062.","journal-title":"JCI Insight"},{"issue":"11","key":"1621_CR58","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s00262-019-02374-0","volume":"68","author":"B Bogen","year":"2019","unstructured":"Bogen B, Fauskanger M, Haabeth OA, Tveita A. CD4(+) T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models. Cancer Immunol Immunother. 2019;68(11):1865\u201373.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"1621_CR59","doi-asserted-by":"publisher","first-page":"e101764","DOI":"10.1371\/journal.pone.0101764","volume":"9","author":"Z Belcaid","year":"2014","unstructured":"Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, Nicholas S, Kellett M, Ruzevick J, Jackson C, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS ONE. 2014;9(7):e101764.","journal-title":"PLoS ONE"},{"issue":"15","key":"1621_CR60","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-17-3821","volume":"78","author":"AJ Rech","year":"2018","unstructured":"Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, Twyman-Saint Victor C, Vonderheide RH. Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer. Cancer Res. 2018;78(15):4282\u201391.","journal-title":"Cancer Res"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01621-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-022-01621-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01621-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T08:10:14Z","timestamp":1663575014000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-022-01621-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1186\/s12951-022-01621-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were approved by the Institutional Animal Care and Use Committee at MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We understand that the text and any pictures published in the article will be freely available on the internet and may be seen by the general public. The pictures and text may also appear on other websites or in print, may be translated into other languages or used for commercial purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"James W. Welsh (JWW) reports research support from GlaxoSmithKline, Bristol Meyers Squibb, Merck, Nanobiotix, RefleXion, Alkermes, Artidis, Mavu Pharma, Takeda, Varian, and Checkmate Pharmaceuticals. JWW serves on the scientific advisory board for Legion Healthcare Partners, RefleXion Medical, MolecularMatch, Merck, AstraZeneca, Aileron Therapeutics, OncoResponse, Checkmate Pharmaceuticals, Mavu Pharma, Alpine Immune Sciences, Ventana Medical Systems, Nanobiotix, China Medical Tribune, GI Innovation, Genentech and Nanorobotics. JWW is on Speaking Engagements for Ventana Medical Systems, US Oncology, Alkermes, and Boehringer Ingelheim. He is co-founder of Healios, MolecularMatch, OncoResponse and serves as an advisor to Astra Zeneca, OncoResponse, Merck, MolecularMatch, Incyte, Aileron and Nanobiotix. JWW holds stock or ownership in Alpine Immune Sciences, Checkmate Pharmaceuticals, Healios, Mavu Pharma, Legion Healthcare Partners, MolecularMatch, Nanorobotics, OncoResponse, and RefleXion. JWW has accepted honoraria in the form of travel costs from Nanobiotix, RefleXion, Varian, Shandong University, The Korea Society of Radiology, Aileron Therapeutics and Ventana. JWW has the following patents; MP470 (amuvatinib), MRX34 regulation of PDL1, XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopalTM. The rest of the authors disclosed no competing interests. Sebastien Paris and Jordan DA SILVA are employees of Nanobiotix.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"417"}}